Overview

A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

Status:
Recruiting

Trial end date:
2023-10-07

Target enrollment:

Participant gender:

Summary

This study will test whether daily use of azithromycin will reduce the rate of exacerbations and improve lung ventilation and perfusion assessed by XE-MRI. The sensitivity of XE-MRI to detect COPD progression will be compared with standard clinical assessment measures including standard lung function tests, 6 minute walk test, and patient reported quality of life.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Azithromycin
Xenon